AstraZeneca
NEWS
The FDA accepted Merck & Co.’s supplemental Biologics License Application and granted Priority Review for Keytruda in advanced cervical cancer.
Merck and Tokyo-based Eisai Co. have signed a strategic collaboration deal to develop and commercialize Lenvima with Merck’s anti-PD-1 drug Keytruda.
Giuseppe Ciaramella, formerly chief scientific officer of Moderna Therapeutics’ Valera unit, has left for an unidentified stealth-mode biotech startup.
While the focus has been on M&A activity, Venture Capital firms have been investing billions in Biotech companies in 2018.
Viela Bio was spun out of AstraZeneca’s MedImmune with a Series A financing of up to $250 million.
Eli Lilly and Company published results from a new Phase IIIb clinical trial of Trulicity (dulaglutide) in combination with a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, which has shown improved blood sugar control in adults with type 2 diabetes.
The U.S. Food and Drug Administration (FDA) approved AstraZeneca’s Imfinzi to treat patients with unresectable Stage III non-small cell lung cancer (NSCLC).
AstraZeneca did not immediately respond to a request for comment.
Failing numbers are putting a strain on CEO Pascal Soriot’s pledge of achieving $45B of annual revenue by 2023.
JOBS
IN THE PRESS